With competitors circling, ViiV wins another label update for long-acting HIV injectable Cabenuva
Just over a year after it was initially approved, GSK’s HIV unit ViiV Healthcare has found yet another way to make Cabenuva’s label even more attractive.
Cabenuva consists of two extended-release injectables: cabotegravir, which is developed by ViiV, and rilpivirine from J&J’s Janssen which is also marketed individually under the brand names Edurant and Rekambys. Previously, patients starting out on the long-acting HIV treatment were required to first take cabotegravir and rilpivirine by mouth for one month to assess their tolerability of the medicines before moving on to injections.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.